ImmunityBio
IBRX
63 hedge funds and large institutions have $56.1M invested in ImmunityBio in 2017 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 23 increasing their positions, 14 reducing their positions, and 7 closing their positions.
86% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 7
64% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 14
11% more funds holding
Funds holding: 57 → 63 (+6)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
3.41% less ownership
Funds ownership: 19.11% → 15.71% (-3.4%)
33% less capital invested
Capital invested by funds: $83.2M → $56.1M (-$27.1M)
95% less call options, than puts
Call options by funds: $4K | Put options by funds: $80K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.14M |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
+$384K |
| 3 |
VIA
Vident Investment Advisory
Alpharetta,
Georgia
|
+$356K |
| 4 |
Morgan Stanley
New York
|
+$220K |
| 5 |
Renaissance Technologies
New York
|
+$207K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WCM
Wildcat Capital Management
New York
|
-$12.2M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.72M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$589K |
| 4 |
BlackRock
New York
|
-$421K |
| 5 |
SG Americas Securities
New York
|
-$270K |
IBRX Hedge Fund Activity: Q4 2017 in Review
63 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in ImmunityBio (IBRX) for Q4 2017, worth a combined $56.1M — down 33% from $83.2M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new IBRX positions and 7 closed out — a net gain of 6 holders — while 23 added to existing stakes and 14 trimmed.
The largest buyer was Vanguard Group, adding an estimated $1.14M. The largest seller was Wildcat Capital Management, cutting an estimated $12.2M.
- 63 institutional investors held ImmunityBio (IBRX) as of Q4 2017, up from 57 in Q3 2017.
- Funds reported $56.1M of ImmunityBio stock for Q4 2017, down 33% quarter-over-quarter.
- 13 funds opened new ImmunityBio positions in Q4 2017 and 7 closed out, a net change of +6 holders.
- The largest ImmunityBio buyer in Q4 2017 was Vanguard Group, an estimated $1.14M added.
- The largest ImmunityBio seller in Q4 2017 was Wildcat Capital Management, an estimated $12.2M sold.
Based on aggregated 13F filings for Q4 2017.